Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Okayama University research: A novel 3D cell culture model sheds light on the mechanisms driving fibrosis in pancreatic cancer


News provided by

Okayama University

28 Aug, 2020, 10:43 GMT

Share this article

Share toX

Share this article

Share toX

OKAYAMA, Japan, Aug. 28, 2020 /PRNewswire/ -- In a recent study published in Biomaterials, researchers at Okayama University created a new 3D cell culture model of pancreatic cancer that closely mimics the "fibrotic" tissue characteristically observed in patients.

Pancreatic cancer is a lethal condition with a very poor prognosis—only ~9% of patients live to see another 5 years after diagnosis. A prime feature of pancreatic cancer is the presence of fibrotic tissue within the tumors. This fibrotic tissue is akin to the scarring that surrounds a wound. Fibrotic tissue entraps the cancer cells within it, making it difficult to therapeutically target these cells. Thus, understanding the mechanisms behind fibrotic tissue development is imperative for creating effective treatment strategies. Professor Mitsunobu R. Kano and Assistant Professor Hiroyoshi Y. Tanaka from Okayama University and colleagues have now created a three-dimensional (3D) cell culture model of pancreatic cancer in the laboratory which closely replicate the fibrotic nature of the tumors.

Fibrotic tissue develops when cancer cells and specialized cells called fibroblasts closely interact with each other. The patterns of fibrotic tissue seen in pancreatic cancer vary greatly from patient to patient. The researchers started by analyzing patient tumor samples and found that fibrotic tissue took up as little as 40% and as much as 80% of the space within tumors. For the 3D cell culture model to truly mimic the cancer, it would need to reflect this wide range in the amount of fibrotic tissue observed. To achieve this, the team tried seeding pancreatic cancer cells and fibroblasts at different ratios. Indeed, by trying various ratios, the team could create 3D pancreatic cancer tissues with any given amount of fibrotic tissue—most importantly within the clinically observed range.

The fibroblasts within these models were subsequently scrutinized to unravel cellular changes driving fibrotic tissue development. It was found that two proteins, namely, SMAD2/3 and YAP were the driving force behind such changes. These two proteins, however, did not act alone: the combined activity of SMAD2/3 and YAP were necessary for the fibroblasts to acquire the abnormal characteristics seen in tumor tissue. A host of cellular signaling systems were in place to enable the function of SMAD2/3 and YAP—some of these systems were common while others were unique to each protein.

Cell culture models of pancreatic cancer play an indispensable part in understanding the disease since they allow mechanistic analyses at a detail that would otherwise be difficult to achieve in studies using laboratory animals or clinical specimens. However, cell culture models to date generally failed to recreate the characteristic, densely fibrotic tissue observed in pancreatic cancer, much less the variability observed between patients. The 3D cell culture model of pancreatic cancer developed in this study overcomes these issues. The new model may enable researchers to understand the differences between tumors showing various degrees of fibrosis and potentially customize strategies to target them. "Our novel model will be useful in promoting the understanding of the complex mechanisms by which the fibrotic stroma develops and how it might be therapeutically targeted", conclude the researchers.

Background

Pancreatic cancer and fibrotic tissue: Pancreatic cancer is one of the most difficult to treat cancers. This is in large part due to the dense, fibrotic tissue present within the tumor.

Fibrosis is a biological process that occurs in damaged internal organs (such as the pancreas) when wound healing mechanisms go awry. Although fibrosis initiates as a process that protects a damaged organ, it sometimes also ends up creating an environment that promotes the growth of cancer cells. Thus, fibrotic tissue is closely associated with the presence and spread of pancreatic cancer. Fibrotic tissue also facilitates drug resistance thereby preventing the cancer cells from responding to any medication. Fibrotic tissue is therefore a huge barrier to understanding the complexities of pancreatic cancer and developing therapeutic strategies.

Link to figure

https://www.okayama-u.ac.jp/up_load_files/research_highlights/113_image_1.jpg

Caption

Pancreatic cancer cells (green areas) and fibroblasts (non-green areas) were mixed in specialized culture vessels to create a novel three-dimensional cell culture model of pancreatic cancer in the laboratory. The cells were mixed at various ratios to enable the tweaking of the amount of fibrosis, from almost no fibrotic tissue (bottom panel, leftmost image) to almost completely fibrotic tissue (bottom panel, 2nd image from the left). When cultured together with cancer cells, fibroblasts began to express a protein characteristic of cancer tissue (red) that was not observed when fibroblasts were cultured alone (bottom panel, left most image). The model thus successfully captures and allows the analysis of the interactions between cancer cells and fibroblasts that drive the formation of fibrotic tissue.

Reference

Hiroyoshi Y. Tanaka, Tsuyoshi Kurihara, Takuya Nakazawa, Michiya Matsusaki, Atsushi Masamune, Mitsunobu R. Kano. Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements. Biomaterials, 251, August 2020, 120077.

DOI : 10.1016/j.biomaterials.2020.120077

https://www.sciencedirect.com/science/article/pii/S0142961220303239

Reference (Okayama Univ. e-Bulletin): Professor KANO's team

OU-MRU Vol.62:3D tissue model offers insights into treating pancreatic cancer

Further information

Okayama University

1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan

Public Relations Division

E-mail: www-adm@adm.okayama-u.ac.jp

Website: http://www.okayama-u.ac.jp/index_e.html

Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/

Okayama University Medical Research Updates (OU-MRU)

Archive of all volumes:

https://www.okayama-u.ac.jp/eng/research/ou-mru.html

Vol.1:Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells from blood samples for genetic testing

Vol.79:Novel blood-based markers to detect Alzheimer's disease

About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 13,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences.

Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.